Navigation Links
Robert Funari Joins NxStage Board of Directors
Date:1/24/2013

LAWRENCE, Mass., Jan. 24, 2013 /PRNewswire/ -- NxStage® Medical, Inc. (Nasdaq: NXTM), a leading manufacturer of innovative dialysis products, today announced that Robert G. Funari , most recently Chairman of Crescent Healthcare, has been appointed to its Board as an independent director.

(Logo: http://photos.prnewswire.com/prnh/20110503/MM94799LOGO )

Mr. Funari served as Chairman and Chief Executive Officer of Crescent Healthcare, a Walgreens Company providing integrated pharmacy and nursing solutions in alternate site settings from 2004 to 2012.  Prior to joining Crescent, Mr. Funari was Executive Vice President and Chief Operating Officer (1993-1996) at Syncor International Corporation, a publicly-traded radiopharmacy services company, where he also served as President and Chief Executive Officer (1996-2003).  Mr. Funari was Executive Vice President and General Manager of the Drug Company for McKesson, Inc. and spent more than 18 years in a broad range of leadership positions at Baxter International.   

"With more than 40 years of executive leadership, particularly in the healthcare industry, and a proven track record of strategic planning and implementation, Bob will be valuable in helping us advance our strategic initiatives to build shareholder value for the future," said Jeffrey Burbank , Chief Executive Officer, NxStage Medical, Inc. 

Funari remarked, "NxStage has the technology, talent and resources to make significant advancements in the delivery of renal care for the benefit of dialysis patients around the world.  I believe that the Company is committed to strategic, patient and market-focused initiatives that will enable it to build on its position as one of the most innovative and disruptive technologies in renal care.  I look forward to working with Jeff Burbank and the rest of the team at NxStage."

Mr. Funari served as a director of Beckman Coulter , Inc., a diagnostics and life sciences company, from 2005 to 2011, as well as director of Pope and Talbot, Inc. from 2001 to 2008.  He also served as director of First Consulting Group from 2004 to 2008 and director of Bay Cities National Bank from 1994 to 2011 where he also served as chairman from 2007 to 2011.  He currently sits on the board of directors of a number of non-profit and private companies and is a member of the RAND Healthcare Board of Advisors.

Mr. Funari holds a B.S. from Cornell University and a M.B.A. from Harvard Business School.  Mr. Funari received the Ernst & Young Entrepreneur Of The Year 2010 Award in the Turnaround category in Orange County/Desert cities.

About NxStage Medical

NxStage Medical, Inc. (Nasdaq: NXTM) is a medical device company, headquartered in Lawrence, Massachusetts, USA, that develops, manufactures and markets innovative systems for the treatment of end-stage renal disease, or ESRD, and acute kidney failure. NxStage is leading the development of the home hemodialysis market in the US with the only portable hemodialysis machine, the System One, cleared for home use by the FDA. For more information on NxStage and its products, please visit the company's website at http://www.nxstage.com/.

Forward-Looking Statements

This release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this release that are not clearly historical in nature are forward-looking, and the words "anticipate," "believe," "expect," "estimate," "plan," and similar expressions are generally intended to identify forward-looking statements. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors including those that are discussed in NxStage's filings with the Securities and Exchange Commission, including the Quarterly Report on Form 10-Q for the quarter ended September 30, 2012. NxStage is under no obligation to (and expressly disclaims any such obligation to) update or alter its forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: Kristen K. Sheppard, Esq.
VP, Investor Relations
ksheppard@nxstage.com


'/>"/>
SOURCE NxStage Medical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Announces the Election of Robert G. Savage to its Board of Directors
2. Amarantus BioSciences Appoints Dr. Robert J. Zimmerman as Product Development Advisor
3. Fuse Science, Inc. adds Major General Robert Dickerson (Ret.) to its Advisory Board
4. Robert G. Savage, Former Worldwide Chairman, Johnson & Johnsons Pharmaceuticals Group, Joins Board of Nuovo Biologics, LLC
5. Lilly Announces Retirement of Robert Armitage, Names Michael Harrington Senior Vice President and General Counsel
6. PAREXEL International to Present at Robert Baird Healthcare Conference
7. Lance Armstrong Update: Arrogant Even After Conceding Doping Charges, Asserts Former White House & WADA Spokesman Robert Weiner; Victory for Clean Sport but "Dark Message" Is Science Must Catch Up to Masking Agents Allowing Cheating
8. ARAMARK Healthcare Technologies Taps Robert Steele to Lead ReMedPar
9. ReShape Medical Appoints Robert E. Grant to Board of Directors
10. B. Braun Joins National Health Organization Supporting Environmental Practices
11. University of Pennsylvania joins Actinium Pharmaceuticals Multicenter Actimab-A Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... Research and Markets has announced the addition of the ... to their offering. ... World Market for Companion Diagnostics covers the world market for ... report includes the following: , World IVD ... (N. America, EU, ROW), 2015-2020 , World IVD Companion ...
(Date:6/24/2016)... 2016  Arkis BioSciences, a leading innovator in ... durable cerebrospinal fluid treatments, today announced it has ... is led by Innova Memphis, followed by Angel ... investors.  Arkis, new financing will accelerate the commercialization ... release of its in-licensed Endexo® technology. ...
(Date:6/23/2016)... 2016 Research and Markets has ... by Type (Organic Chemical (Sugar, Petrochemical, Glycerin), Inorganic Chemical), ... Parenteral) - Global Forecast to 2021" report to ... The global pharmaceutical excipients market is projected to reach ... 6.1% in the forecast period 2016 to 2021. ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... ... June 24, 2016 , ... Those who have experienced traumatic events ... turn to unhealthy avenues, such as drug or alcohol abuse, as a coping mechanism. ... tools for healthy coping following a traumatic event. , Trauma sufferers tend to feel ...
(Date:6/24/2016)... MIAMI, Fla. (PRWEB) , ... June 24, 2016 , ... ... Florida Trend magazine’s 2016 Legal Elite. The attorneys chosen by their peers for this ... of Florida. , Seven Greenberg Traurig Shareholders received special honors as members of this ...
(Date:6/24/2016)... , ... June 24, 2016 , ... People across the ... Genome magazine’s Code Talker Award, an essay contest in which patients and their families ... to be presented at the 2016 National Society of Genetic Counselors (NSGC) Annual Education ...
(Date:6/24/2016)... ... 24, 2016 , ... Strategic Capital Partners, LLC (SCP) in ... investment capital for emerging technology companies. SCP has delivered investment events and ... more than a million dollars of capital investment for five companies. ...
Breaking Medicine News(10 mins):